ModifiedBlue Cross Blue Shield - New MexicoPolicy CPCPLAB059

Diagnosis of Vaginitis

Defines laboratory reimbursement criteria for diagnostic testing of vaginitis for BCBSNM products; applies to providers submitting claims for vaginitis-related tests and to plan-covered members (providers should verify specific product coverage in plan documents).

Policy Summary

PayerBlue Cross Blue Shield - New Mexico

PolicyDiagnosis of Vaginitis

Policy CodePolicy CPCPLAB059

Change TypeRevised — reimbursement stance updated

Effective DateMar 15, 2024

Next Review DateN/A

Key ActionSubmit claims with accurate documentation using valid HIPAA-approved codes; NAAT panels detecting multiple vaginitis pathogens may be reimbursable when criteria met.

SourceLink

POLICY UPDATE CHANGES

Reimbursement information revised to allow that NAAT panel testing designed to detect more than one type of vaginitis (VVC, BV, and/or trichomoniasis) may be reimbursable.

Title changed from 'Diagnosis of Vaginitis Including Multi-target PCR Testing' and reimbursement language clarified with added specific NAAT testing language to items #8 and #9.

10+reimbursable test categories or examples

11non-reimbursable items

25+procedure codes included

may be reimbursable

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Vaginitis Testing

Reimbursable and non-reimbursable tests

Covered when the following symptom‑ or risk‑based conditions are met; specific items are designated non‑reimbursable where noted.

ref

title

ref_broken_placeholder

Procedure and Test Codes

Procedure / laboratory codes listedmixed

81513
81514
82120
83986
87070
87149
87150
87210
87480
87481

1–10 of 26

1/3

Examples of reimbursable NAAT panelsmixedCovered

No codes listed

Documentation and Billing Requirements

Documentation Required

Submit accurate documentation and HIPAA-approved codes; claims subject to plan documents

Providers must submit accurate documentation of services performed and submit claims using valid code combinations from HIPAA‑approved code sets. Claims are subject to plan documents, provider contracts, coding edit protocols, and may be reviewed; BCBSNM may request additional documentation and exercise discretion in interpreting and applying this policy.

Use industry-standard coding guidelines and HIPAA‑approved code sets (CPT, HCPCS, ICD-10, NDC, DRG, etc.).
Claims are subject to code edit protocols and claim review against plan documents, provider contracts, medical policies, and coding software logic.
Be prepared to provide additional documentation upon request.

Billing Rule

Definitions and Test Types

inv-07: Basic vaginitis diagnostic tests — descriptions of wet mount, KOH, pH, amine testing and point-of-care/lab techniques

Wet mount (saline)Microscopic examination of vaginal fluid using saline to detect motile trichomonads and clue cells; listed as a reimbursable point-of-care/lab technique for symptomatic vaginitis.

KOH (hydrogen peroxide) wet mountPotassium hydroxide preparation of vaginal discharge to visualize budding yeast and pseudohyphae for suspected vulvovaginal candidiasis; included as a reimbursable diagnostic test for symptomatic individuals.

pH testingMeasurement of vaginal fluid pH to help differentiate BV (typically pH >4.5) from candidiasis; listed as a reimbursable initial evaluation test for symptomatic vaginitis.

Amine (whiff) testChemical detection of volatile amines in vaginal fluid (positive ‘whiff’ suggests BV); identified in policy as a reimbursable test for symptomatic individuals.

Microscopic examination of vaginal fluidsDirect microscopy to assess leukocytes, clue cells, yeast, and other findings as part of wet-mount/KOH evaluation; reimbursable for symptomatic evaluation.

Policy Summary

PayerBlue Cross Blue Shield - New Mexico

PolicyDiagnosis of Vaginitis

Policy CodePolicy CPCPLAB059

Change TypeRevised — reimbursement stance updated

Effective DateMar 15, 2024

Next Review DateN/A

Key ActionSubmit claims with accurate documentation using valid HIPAA-approved codes; NAAT panels detecting multiple vaginitis pathogens may be reimbursable when criteria met.

SourceLink

On This Page

inv-08: Molecular diagnostic tests — NAAT/PCR descriptions for Trichomonas, Candida, Gardnerella, etc.

NAAT / PCR for Trichomonas vaginalisNucleic acid amplification or PCR-based assays to detect Trichomonas vaginalis; identified in the policy as reimbursable for symptomatic individuals and for targeted screening in persons with risk factors.

NAAT / PCR for Candida speciesPCR-based identification of Candida to confirm diagnosis and to identify non‑albicans species in complicated vulvovaginal candidiasis; listed as reimbursable when clinically indicated.

NAAT panels for BV and vaginitisMolecular panels (single- or multitarget) that detect bacterial vaginosis markers (examples: Aptima BV, OneSwab BV Panel, SureSwab Advanced BV) are identified as reimbursable for symptomatic BV.

Multi-target vaginal NAAT panelsPanels designed to detect multiple causes of vaginitis (VVC, BV, and/or trichomoniasis; e.g., BD MAX Vaginal Panel, NuSwab VG, Xpert Xpress MVP) are noted in the policy as potentially reimbursable.

Clinical validation and performance referencesPolicy cites prospective evaluations and clinical validation studies of molecular assays for vaginitis diagnosis to support use of NAAT/PCR methods.

inv-09: Sialidase testing — brief definition of sialidase activity measurement for BV diagnosis

Sialidase activity measurementBiochemical assay measuring sialidase activity in vaginal fluid used to aid diagnosis of bacterial vaginosis; listed as a reimbursable diagnostic test for symptomatic individuals.

Use contextSpecified for individuals with symptoms of vaginitis when BV is suspected as part of the diagnostic workup.

Relation to other testsPresented alongside NAAT/PCR and microscopic methods as an accepted laboratory option to support BV diagnosis when clinically indicated.

inv-10: Cited literature and test documentation supporting diagnostic performance and guidelines for vaginitis testing (molecular assays, BV tests, clinical guidelines)

Clinical validation studiesRichter et al. (2019) and Schwebke et al. (2018, 2020) prospective evaluations and clinical validation of molecular assays for vaginitis are cited as supporting evidence for NAAT performance.

BV diagnostic test evaluationsMyziuk et al. (2003) and BVBlue evaluations, plus studies of BV-specific molecular tests (Menard et al., 2008/2010) cited for BV test performance and quantification approaches.

Test manufacturer directoriesManufacturer/test resources (e.g., Quest test listings for SureSwab Advanced BV and SureSwab Vaginitis) are referenced for assay descriptions and methods.

Guidelines and reviewsIDSA/ASM laboratory utilization guidance (Miller et al. 2018), USPSTF and specialty guideline citations (Workowski & Bolan 2015; van Schalkwyk & Yudin 2015; Sobel reviews) referenced to support diagnostic recommendations.